TARGET Study Finds Major Differences between Childhood and Adult AML
January 30, 2018, by NCI Staff
An NCI-funded study has found that, at the genetic level, acute myeloid leukemia (AML) differs greatly between younger and older patients.
“AML in younger patients and AML in older patients are entirely distinct diseases,” said the study’s senior investigator, Soheil Meshinchi, M.D., Ph.D., of Fred Hutchinson Cancer Research Center. “It’s almost like comparing breast cancer to colon cancer.”
The findings, published in the January 2018 issue of Nature Medicine, come from a genomic analysis of nearly 1,000 children and young adults with AML. The study is part of the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) initiative, a collaborative effort between NCI and the Children’s Oncology Group (COG) to better understand the biology of several high-risk or hard-to-treat pediatric cancers.
“This [study] can inform where therapeutic development should focus in order to better target pediatric AML,” said Yana Pikman, M.D., a pediatric oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, who was not involved in the study.
Therapies that are tailored to the biology of AML in children may be the best hope for treating the disease, the researchers believe. They have already used some of the early study findings to influence clinical trials of potential targeted therapies for AML.
Challenging Assumptions about AML
Acute myeloid leukemia, a cancer of the bone marrow and blood, occurs most frequently in adults over the age of 60. Though it is rare, AML also develops in younger adults and children, sometimes as early as a few days after birth.
The treatment options for young patients with AML include intensive chemotherapy and bone marrow transplantation. In the early 1980s, approximately 30% of children with AML survived 5 years after their diagnosis, and in more recent years, the rate has increased to around 65%.
Despite this improvement, there has been limited progress in identifying effective targeted therapies due to "an inadequate understanding of the biology of childhood AML," the TARGET investigators wrote.
"Generally, people think that AML in children is the same disease as in older adults, just less common," explained Dr. Meshinchi. "So, until now, most of the studies, discoveries, and treatments [for AML] have been developed in older patients. The assumption is that whatever we find in an older population can be used to treat younger patients," he continued.
But earlier studies by Dr. Meshinchi and his colleagues showed that some of the most common genetic features of adult AML are completely absent in childhood AML, suggesting that the biological characteristics of this leukemia may differ by patient age.
Toward a Better Understanding of Childhood AML
For the TARGET project, the researchers analyzed the genomic (DNA, RNA, and epigenetic) features of cancer cells from infants (less than 3 years old), children (3–14 years old), and adolescents and young adults (15–39 years old) with AML.
In addition to identifying small DNA mutations, the investigators also took note of big changes in chromosome structure (known as structural alterations), such as the loss, amplification, or relocation of a chunk of a chromosome.
The genomic characteristics of childhood AML differed broadly among study participants, the researchers discovered. For example, only a handful of the same mutations and structural alterations were present in more than 5% of patients in the study.
The low frequency of recurring mutations and alterations represents "a substantial challenge to advancing therapies for pediatric AML," noted Andrew Brunner, M.D., and Timothy Graubert, M.D., of Massachusetts General Hospital, in a commentary that accompanied the TARGET study.
Because the genetic features of each child's AML are unique, "no single treatment strategy is likely to be effective for all pediatric AML [patients]," the TARGET researchers wrote.
The team also identified many fusion genes, which can form when chromosome pieces shift and have been found to drive the growth of many blood cancers. The fusion proteins produced by such fusion genes are ideal drug targets because they are exclusive to cancer cells, so drugs that target them are less likely to harm normal cells, Dr. Meshinchi explained.
"The critical question is: Is it possible to target these fusion proteins directly?" he asked. Dr. Meshinchi and his team are exploring this possibility, as well as the potential for targeting fusion proteins indirectly by going after the genes and proteins that they regulate.
Same Name, Different Disease
When the team compared the genomic characteristics of pediatric AML to those of adult AML, as identified by a study from The Cancer Genome Atlas (TCGA), they discovered significant differences.
The most critical difference, noted Dr. Meshinchi, was: Whereas mutations were much more common than structural alterations in adults with AML, the opposite was true in children. For example, the researchers found nearly ten times more structural alterations than DNA mutations in infants with AML.
The finding suggests that, in young children, structural alterations are potent enough to cause cancer on their own, he explained. In adults, AML is caused by the accumulation of multiple mutations and alterations over the course of a lifetime.
The researchers also found that the few DNA mutations that were present in pediatric AML were different from those in adult AML—both in terms of where and how frequently the mutations occurred. For example, mutations in the NRAS gene (a gene that controls cell growth and death) were much more common in pediatric AML than adult AML. There was some overlap in DNA mutations identified in adult and pediatric AML patients, however, particularly between the adolescent and young adults group and older adults.
Said Dr. Pikman, "people often say that kids are not little adults, and I think that this [study] very clearly shows that."
Together, the study results underscore the fact that many AML treatments that are developed for adults with the hope that they can "trickle down" to children and young adults may not be effective for pediatric AML, Dr. Meshinchi stressed.
The study findings provide a "better understanding of what initiates or sustains these cancers," which will help guide the development of new treatments, said study investigator Daniela S. Gerhard, Ph.D., of NCI’s Office of Cancer Genomics.
In fact, TARGET and COG researchers are already planning several clinical trials based on these findings. For example, the researchers found high levels of a protein called mesothelin—which is sometimes expressed by lung cancer cells—in some younger patients with AML. Dr. Meshinchi and his colleagues are working with Bayer to bring a mesothelin-targeting drug the company has developed for lung cancer into clinical trials for children and young adults with relapsed AML.
Researchers at COG are also planning a clinical trial that will investigate whether comprehensive genetic tests such as those used in the TARGET study can help guide treatment selection and improve patient outcomes.
The next step is to continue "mining the data" from the TARGET study to identify patterns, associations, and potential drug targets, Dr. Gerhard said. And because the data are available to qualified researchers (in ways that protect patient privacy), more researchers have the opportunity to build on these initial results.
Dr. Pikman, who leads a multi-institutional study investigating the efficiency of genomic tests for matching patients with leukemia to targeted therapy, is already using some of the data to guide her research.